Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze REGN Regeneron Pharmaceuticals, Inc.. Please read: https://finlab.finance/en/setup?stock=REGN

No install, open FinLab Studio

REGN

Regeneron Pharmaceuticals, Inc. Healthcare As of 2026-07-31 Updated daily after market close

steady quality, premium valuation.

1 active signal
EPS surprise beat
This page refreshes daily after the close. Add Regeneron Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.
Valuation 43Quality 80Growth 56Momentum 71Risk / liquidity 80

Is Regeneron Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

  • Quality is above average. Operating margin sits near the 79th percentile. TTM ROE is about 14.1%.

  • Valuation is expensive. TTM P/E is in the 71th percentile, above most peers.

  • Recent volatility is moderate. 60-day annualized volatility is near the 37th percentile. Average 20-day dollar volume is about $533.3M.

  • Signals are active now. EPS surprise beat currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

EPS surprise beat

Active · now 40.649606299212586%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

34 historical occurrences (since 2015-08-04)
Average forward return after EPS surprise beat。20-day: Win 54.8%, Sample 31, Median +2.65%, Excess +0.15%, Beat mkt rate 58.1%；60-day: Win 48.4%, Sample 31, Median -1.31%, Excess -2.3%, Beat mkt rate 32.3%；120-day: Win 60%, Sample 30, Median +4.84%, Excess -4.39%, Beat mkt rate 53.3%

120 days after: historical avg +2.69%

20-day +1.84%
60-day +0.69%
120-day +2.69%
20-day
60-day
120-day
Win
54.8%
48.4%
60%
Sample
31
31
30
Median
+2.65%
-1.31%
+4.84%
Excess
+0.15%
-2.3%
-4.39%
Beat mkt rate
58.1%
32.3%
53.3%

Over 30 occurrences, 120-day forward avg gained 2.69%, lagged the market by 4.39 pts; win rate 60%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 501+21.1% +21.1% 92.2% +17.3%
20-40 317+11% +11.5% 85.5% -8.7%
40-60 You are here236+18.9% +24.3% 75.4% -10.4%
60-80 268-21% -25.6% 14.6% -42.6%
80-100 52-50.7% -51.3% 0% -62.7%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 18.58, placing it in the 45.3 own-history percentile, inside the 40-60 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+11.7%
Win rate 78.7% Excess +11%
342d
Now
+4.5%
Win rate 64% Excess -9.2%
333d
-10.4%
Win rate 41% Excess -21.1%
200d
60-day momentum down
+11%
Win rate 65.8% Excess +2.4%
430d
-7.4%
Win rate 43.5% Excess -12.4%
161d
Insufficient data
(28d)

Currently in “Middle × 60-day momentum up”: across 333 historical days, 120-day forward avg gained 4.5%, win rate 64%, lagged the market by 9.2%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

18 times historically; 60-day forward avg -0.29%, win rate 44.4%, beating the market by -3.92 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

26 times historically; 60-day forward avg -0.14%, win rate 42.3%, beating the market by -0.57 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

8 times historically; 60-day forward avg +2.47%, win rate 50%, beating the market by -0.41 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.